|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 471/04 | (2006.01) |
| A61K 31/4738 | (2006.01) | ||
| A61K 31/497 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3640251 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19189010.2 |
| Date of filing the European patent application | 2017-10-13 | |
| (97) | Date of publication of the European application | 2020-04-22 |
| (45) | Date of publication and mention of the grant of the patent | 2021-12-08 |
| (46) | Date of publication of the claims translation | 2022-03-10 |
| (30) | Number | Date | Country code |
| 201662411799 P | 2016-10-24 | US | |
| 201662435159 P | 2016-12-16 | US |
| (72) |
SCOTT, James Stewart , GB
BARLAAM, Bernard Christophe , GB
YANG, Bin , US
MOSS, Thomas Andrew , GB
HUGHES, Samantha Jayne , GB
NISSINK, Johannes Wilhelmus Maria , GB
O'DONOVAN, Daniel Hillebrand , GB
|
| (73) |
Astrazeneca AB ,
151 85 Södertälje,
SE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | 6,7,8,9-Tetrahidro-3H-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui |
| 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER |
| Payment date | Validity (years) | Amount | |
| 2025-09-23 | 9 | 208.00 EUR |
| 2026-10-13 |